2026 | INDUSTRY INSIGHTS
U.S. Continuous Glucose Monitoring (CGM) Market Report: Growth Outlook and Key Trends
2026
Industry Insights SUMMARY1 The U.S. Continuous Glucose Monitoring (CGM) market is on a strong upward trajectory, with a compound annual growth rate (CAGR) of 9.5% through 2033. Despite this impressive growth, the market remains significantly underpenetrated, with only about 25% of eligible patients currently using CGM systems. With a total addressable market estimated at over $20 billion, there is substantial room for expansion, particularly as awareness, accessibility, and innovation continue to improve.
MARKET OVERVIEW2 The CGM market in the United States is expanding rapidly, driven by the increasing prevalence of diabetes and the growing demand for real-time glucose monitoring solutions. With over 34 million Americans living with diabetes, the need for effective, continuous monitoring tools is more critical than ever. The market’s projected growth from $3.7 billion in 2024 to $8.4 billion by 2033 underscores the increasing reliance on CGMs as a standard of care for both type 1 and type 2 diabetes management.
The market’s projected growth from $3.7 billion in 2024 to $8.4 billion by 2033
$8.4
KEY GROWTH DRIVERS Several factors are fueling the growth of the CGM market. First and foremost is the rising prevalence of diabetes. According to the CDC, more than 1.2 million Americans have type 1 diabetes, while over 33 million are living with type 2 diabetes. This growing patient population is driving demand for more effective and userfriendly monitoring solutions. Technological advancements are also playing a pivotal role. Innovations such as implantable sensors, extended sensor wear times, and improved accuracy are making CGMs more appealing and accessible. Additionally, expanded insurance coverage, including Medicare reimbursement, is reducing financial barriers and enabling broader adoption. Another emerging driver is the potential for CGM use in hospital settings, where continuous monitoring can improve outcomes for inpatients with diabetes.
EMERGING TRENDS The reintroduction of competitive bidding for CGMs will reshape the industry across multiple dimensions: pricing, supplier participation, patient access, and manufacturer strategy. While CMS aims to control costs and promote standardization, the cumulative effects like supplier consolidation, financial strain on DME providers, disruptions in patient care, and declining incentives for innovation pose risks. A large portion of the CGM patient population between ages 18-64 years old has private insurance, providing protection from any Medicare fee-for-service legislation like competitive bidding.
1 News • 20 Jan 25 • “United States Continuous Glucose Monitoring (CGM) Market Worth U.S. $8.4 Billion by 2033 Exclusive Report by DPI Research” 2 United States Continuous Glucose Monitoring (CGM) Research Report 2025: Market to Grow by $4.7 Billion to Reach $8.4 Billion by 2033 with Abbott Laboratories, Dexcom, Medtronic, Senseonics Leading - ResearchAndMarkets.com
2026 |
INDUSTRY INSIGHTS | U.S. Continuous Glucose Monitoring (CGM) Market Report: Growth Outlook and Key Trends
As the Medicare Advantage (MA) population grows and benefits become more flexible, the CGM market will increasingly rely on MA compared to fee-for-service (FFS) Medicare. In 2017, 91% of CGM claims across FFS Medicare, MA, and Medicaid were patients enrolled in FFS Medicare. By 2022, this proportion shrank to 52%, reflecting the rise of MA and Medicaid claims. For adults ages 18-64 years old with diabetes, most had private insurance (57.4%), followed by Medicaid/other public insurance (23.9%), Medicare coverage (16.0%), and military benefits (4.1%).
MARKET OPPORTUNITIES Looking ahead, the CGM market presents numerous opportunities for growth. The implantable CGM segment alone is expected to reach a $5 billion market in North America and Europe by 2035, driven by innovations in sensor longevity and convenience. Perhaps most notably, the non-insulin-dependent type 2 diabetes population remains largely untapped, representing a significant growth frontier for CGM technologies.
KEY TAKEAWAYS The U.S. CGM market is entering a period of robust expansion, supported by technological innovation, favorable policy changes, and increasing demand for better diabetes management tools. As the market continues to evolve, the focus will be on improving user experience, expanding access, and integrating CGMs into broader healthcare ecosystems. With a large addressable market and strong momentum, CGMs are set to become a cornerstone of modern diabetes care in the years ahead.
2026 |
INDUSTRY INSIGHTS | U.S. Continuous Glucose Monitoring (CGM) Market Report: Growth Outlook and Key Trends
VGM Industry Insights provides data-driven analysis and trends within the durable medical equipment, prosthetics, orthotics, and supplies (DMEPOS) sector. Our focus areas include market trends, innovation, and strategic decision-making, helping stakeholders stay informed and competitive. We are committed to a forward-thinking approach, continuously monitoring industry developments to drive progress and innovation.
ALAN MORRIS SVP of Strategy
TYLER COULANDER Market Strategy Manager